Bristol-Myers Squibb stock falls on lung cancer drug study result - MarketWatch

Bristol-Myers Squibb stock falls on lung cancer drug study result  MarketWatch

Bristol-Myers Squibb Co. fell in the extended session Wednesday after the drug maker said its lung cancer drug did not achieve one of its goals in a late-stage ...



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...